Sunny Pharmtech's earnings have been declining at an average annual rate of -10.4%, while the Pharmaceuticals industry saw earnings growing at 9.9% annually. Revenues have been growing at an average rate of 1.9% per year.
Key information
-10.37%
Earnings growth rate
-6.75%
EPS growth rate
Pharmaceuticals Industry Growth
18.53%
Revenue growth rate
1.94%
Return on equity
-40.01%
Net Margin
-119.38%
Last Earnings Update
31 Dec 2025
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sunny Pharmtech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
TPEX:6676 Revenue, expenses and earnings (TWD Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
253
-302
164
227
30 Sep 25
272
-286
171
229
30 Jun 25
290
-270
178
231
31 Mar 25
354
-213
174
225
31 Dec 24
418
-156
170
219
30 Sep 24
452
-103
162
207
30 Jun 24
485
-50
153
195
31 Mar 24
457
-57
151
202
31 Dec 23
429
-63
149
209
30 Sep 23
405
-90
147
224
30 Jun 23
382
-116
145
240
31 Mar 23
371
-143
142
248
31 Dec 22
360
-170
138
256
30 Sep 22
317
-176
136
226
30 Jun 22
274
-182
133
197
31 Mar 22
257
-179
127
184
31 Dec 21
241
-175
120
171
30 Sep 21
277
-162
117
175
30 Jun 21
312
-150
113
178
31 Mar 21
366
-126
115
180
31 Dec 20
420
-102
116
182
30 Sep 20
426
-112
114
187
30 Jun 20
432
-121
111
192
31 Mar 20
333
-174
107
199
31 Dec 19
234
-226
104
206
30 Sep 19
194
-260
103
251
30 Jun 19
153
-295
103
296
31 Mar 19
148
-297
111
301
31 Dec 18
143
-300
119
305
30 Sep 18
86
-302
119
258
30 Jun 18
30
-304
118
211
31 Mar 18
26
-287
106
194
31 Dec 17
22
-269
93
177
30 Sep 17
18
-256
80
177
30 Jun 17
15
-243
67
176
31 Mar 17
20
-235
59
186
31 Dec 16
24
-227
51
196
31 Dec 15
15
-146
39
122
Quality Earnings: 6676 is currently unprofitable.
Growing Profit Margin: 6676 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6676 is unprofitable, and losses have increased over the past 5 years at a rate of 10.4% per year.
Accelerating Growth: Unable to compare 6676's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6676 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-5%).
Return on Equity
High ROE: 6676 has a negative Return on Equity (-40.01%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/03 00:54
End of Day Share Price
2026/06/03 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sunny Pharmtech Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.